Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05020288
Other study ID # ITP-Orelabrutinib
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date September 1, 2021
Est. completion date June 1, 2024

Study information

Verified date August 2021
Source Shandong University
Contact Ming Hou, MD,PhD
Phone 0531-82169879
Email houming@medmail.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

BTK participates in a variety of signal transduction of innate and adaptive immunity, and has an important role in cell proliferation, differentiation and apoptosis. The impact of BTK inhibitors on hematological malignancies and autoimmune diseases has been well studied. This project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of the selective BTK inhibitor Orelabrutinib in the management of refractory ITP.


Description:

The investigators are undertaking a prospective, open-lable, multicentre trial of 40 refractory ITP adult patients in China. Eligible participants will receive Orelabrutinib in 50 mg po. qd, every 4 weeks for one cycle and it will be given 3 cycles. For non-responders who were well tolerated at 12 weeks of follow-up, the treatment could be extended to 6 cycles. The treatment will be discontinued after 6 months without blood index reaction. In order to report the efficacy and safety of Orelabrutinib in the management of refractory ITP, platelet count, bleeding and other symptoms will be evaluated before and after treatments. Adverse events are also recorded throughout the study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date June 1, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Meet the diagnostic criteria for primary immune thrombocytopenia - To show a platelet count < 30 * 10^9/L, or with bleeding manifestations, or both - Willing and able to sign written informed consent - Meet the diagnostic criteria of refractory ITP according to Chinese guidelines Exclusion Criteria: - Secondary thrombocytopenia - severe immune-deficiency or history of primary immunodeficiency - active or previous malignancy - HIV virus infection, tuberculosis, or other active infection (sepsis, pneumonia, or abscess) - pregnancy or lactation - diabetes - hypertension - cardiovascular diseases - severe liver or kidney function impairment - psychosis - osteoporosis - inflammatory bowel disease or gastric disease - arterial or venous thromboembolism within the 6 months before screening or patients who required anticoagulant treatment - an organ or haematopoietic stem-cell transplantation - neutrophil count of less than 1500 cells per mm³; glycosylated haemoglobin less than 8%; partial thromboplastin time 1·5 times or less the upper limit of normal (ULN) - clinical electrocardiogram changes - neoplastic disease within the past 5 years - corrected QT interval greater than 450 ms for men and greater than 470 ms for women; - substance misuse within the previous 12 months; and those who could not adhere to the protocol or were planning to have a surgical procedure in 6 months.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Orelabrutinib
Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shandong University

Outcome

Type Measure Description Time frame Safety issue
Primary Initial overall response to Orelabrutinib Complete response was defined as a platelet count of 100×10? cells per L or higher and an absence of bleeding. Partial response was defined as a platelet count of 30×10? cells per L or higher, but less than 100×10? cells per L, and at least a doubling of the baseline platelet count and an absence of bleeding. Platelet counts were confirmed on two separate occasions at least 7 days apart when defining complete response or partial response. No response was defined as a platelet count of less than 30×10? cells per L, or less than two-times increase from baseline platelet count, or bleeding. 14 days after the first dose of Orelabrutinib
Primary Sustained overall response to Orelabrutinib Complete response was defined as a platelet count of 100×10? cells per L or higher and an absence of bleeding. Partial response was defined as a platelet count of 30×10? cells per L or higher, but less than 100×10? cells per L, and at least a doubling of the baseline platelet count and an absence of bleeding. Platelet counts were confirmed on two separate occasions at least 7 days apart when defining complete response or partial response. No response was defined as a platelet count of less than 30×10? cells per L, or less than two-times increase from baseline platelet count, or bleeding. A response lasting for at least 6 months without any additional intervention specific to primary immune thrombocytopenia was defined as a sustained response
Secondary Time to response Time from treatment initiation to achieve a complete response or a partial response An average of 6 months
Secondary Duration of response Time from achievement of a complete response or a partial response to the loss of response (platelet count <30×10? cells per L; measured on two occasions more than 1 day apart or the presence of bleeding). through study completion, an average of 1 year
Secondary Therapy associated adverse events Potential adverse events: leukopenia (report in number * 10^9/L, time of occurrence and duration); nausea and diarrhea (report in frequency); infection (report pathogens and infectious diseases). Up to 1 year
See also
  Status Clinical Trial Phase
Completed NCT02287649 - Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP) N/A
Terminated NCT02401061 - PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP Phase 1/Phase 2
Completed NCT02868099 - Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) Phase 3
Completed NCT02556814 - Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Phase 4
Completed NCT02351622 - Caffeic Acid Tablets as a Second-line Therapy for ITP Phase 3
Active, not recruiting NCT04741139 - Post IVIG Medication in Children With Immune Thrombocytopenia Phase 1
Not yet recruiting NCT05468866 - The Expression of Immune Checkpoint CD28 rs1980422-related Single-nucleotide Polymorphisms in the Primary Immune Thrombocytopenia N/A
Not yet recruiting NCT05494307 - The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia Phase 2
Recruiting NCT04993885 - Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Phase 2
Recruiting NCT05281068 - The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia Phase 2
Withdrawn NCT03965624 - Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia Phase 2
Not yet recruiting NCT03252457 - Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP Phase 3
Recruiting NCT05937828 - OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Completed NCT03156452 - Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate Phase 3
Completed NCT03164915 - A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Phase 3
Recruiting NCT02270801 - Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy Phase 3
Withdrawn NCT01976195 - High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP Phase 2
Completed NCT01933035 - Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. N/A
Recruiting NCT02821572 - Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)
Not yet recruiting NCT05562882 - A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia Early Phase 1